TLR7 TLR8 Modulator Compounds Specificity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for modulating Toll-Like Receptors (TLRs) lack effective compounds that can specifically target and modulate these receptors, particularly TLR7 and TLR8, for treating various diseases and disorders.
Innovation Solution
Development of specific compounds, such as those represented by Formula (I-A), which are designed to modulate TLR receptors by administering therapeutically effective amounts of these compounds or their pharmaceutically acceptable salts, thereby acting as TLR receptor agonists or antagonists to treat conditions like infectious diseases, inflammatory diseases, and autoimmune disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If existing methods for modulating TLRs are used, then general immune modulation may be achieved, but specific targeting of TLR7 and TLR8 receptors is insufficient
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular structures (Formula I) that are tailored to interact with particular TLR subtypes (TLR7 and TLR8) rather than providing non-specific immune modulation. The compounds contain specific functional groups and molecular configurations that confer selective affinity for these receptors, enabling precise modulation at the receptor level while maintaining therapeutic versatility across different disease types.
Solution Approach 2:
The patent utilizes parameter changes by systematically varying molecular parameters of the TLR modulators, including substituent groups, molecular weight, and structural configurations. These parameter variations allow the compounds to optimize their binding affinity and efficacy for TLR7 and TLR8 while maintaining pharmacokinetic properties suitable for treating diverse diseases, thereby resolving the contradiction between specificity and versatility.
2Adaptability or versatility
If TLR modulators are developed to treat multiple disease types, then versatility is improved, but compound complexity increases
Solution Approach 1:
The patent applies universality by designing a core molecular scaffold (Formula I) that can serve multiple therapeutic functions. The compounds are capable of modulating TLR7 and TLR8 receptors in different disease contexts, including viral infections, bacterial infections, inflammatory conditions, and autoimmune disorders. This multi-functional capability is achieved through a unified structural platform that can be adapted for various indications without requiring entirely different compound classes.
Solution Approach 2:
The patent utilizes segmentation by dividing the molecular structure into distinct functional components: a core scaffold and variable substituent groups. This segmentation allows independent optimization of different regions - the core structure provides the essential TLR binding capability, while substituent groups can be adjusted to fine-tune specificity, pharmacokinetics, and tissue distribution. This modular approach reduces overall complexity compared to designing entirely new compounds for each disease indication.
3Reliability
If therapeutically effective amounts of TLR modulators are administered, then disease treatment efficacy is improved, but potential harmful effects increase
Solution Approach 1:
The patent applies the inversion principle by considering both agonist and antagonist activities within the same molecular framework. Rather than only stimulating TLRs to enhance immunity, the compounds can also block TLR signaling to prevent excessive immune activation. This dual capability allows the same structural class to treat conditions requiring immune enhancement (infections) and conditions requiring immune suppression (autoimmune disorders), thereby managing harmful effects while maintaining therapeutic efficacy.
Solution Approach 2:
The patent utilizes feedback mechanisms by designing compounds that can be regulated based on disease state and patient response. The modular structure allows for dose adjustment and combination therapies that respond to therapeutic outcomes. Feedback control is implemented through monitoring of immune activation markers and clinical response, enabling dynamic optimization of the therapeutically effective amount to maximize benefit while minimizing harmful effects.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors, including TLR7 and TLR8. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine (formula I) wherein: X3 is N; X4 is N Or CR3; X5 is -CR4=CR5.